Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-idiotype antibody for human CD22 antibody, and application thereof

An antibody and antibody heavy chain technology, applied in applications, specific peptides, recombinant DNA technology, etc., can solve problems such as difficulty in biological activity detection

Active Publication Date: 2014-02-19
SINOMAB BIOSCI
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This feature makes it very difficult to detect the biological activity of SM03 and SM06 mAb products

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-idiotype antibody for human CD22 antibody, and application thereof
  • Anti-idiotype antibody for human CD22 antibody, and application thereof
  • Anti-idiotype antibody for human CD22 antibody, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Example 1. Anti-idiotypic antibodies against human CD22 antibodies in the form of single-chain antibodies

[0113] In this example, the variable region light and heavy chain sequences of the anti-SM03 anti-idiotypic antibody were obtained by using phage display library technology, and the anti-idiotypic single-chain antibody against human CD22 antibody—the soluble scFv expressed by phage #3 was further prepared. Specific steps are as follows:

[0114] 1. Preparation of phage display library by injecting SM03 immunized mice

[0115] About 6 weeks old female Balb / c mice were immunized by intraperitoneal injection of 100ug SM03 monoclonal antibody according to the standard immunization procedure (see "In Antibodies: A Laboratory Manual" published by Cold Spring Harbor Laboratory, USA in 1988), And emulsified with 200uL complete Freund's adjuvant (product of Sigma-Aldrich, USA). The second and third immunizations were carried out after 14 days and 35 days respectively. Th...

experiment example 2

[0124] Experimental example 2, using the soluble scFv expressed by phage #3 in Example 1 to conduct pharmacokinetic research in SM03 clinical trials

[0125] Due to the specificity of the compatible scFv expressed by phage #3 in Example 1 to SM03, it can be used to develop a corresponding detection method to determine the antibody concentration in the serum of patients receiving anti-CD22 antibody treatment, especially to assist clinical practice. required pharmacokinetic studies. A 96-well ELISA plate was coated with the compatible scFv expressed by phage #3 in Example 1. After blocking and washing with BSA, the serum of each blood collection point of patients receiving SM03 treatment was diluted and added to the wells. After incubation at 37°C for 2 hours and thorough washing, HRP-labeled goat anti-human Fc antibody (product of Jackson Immunoresearch) was diluted 1:4000 and added to the wells. After incubation at 37°C for 1 hour, the microtiter plate was washed 5 times, de...

Embodiment 3

[0127] Example 3. Anti-idiotypic antibody IdmG2a / k for human CD22 antibody in the form of murine IgG2a / kappa immunoglobulin molecules

[0128] The preparation of compatible scFv expressed by phage #3 in Example 1 requires a series of complex steps such as bacterial culture, induced expression and collection of inclusion bodies, protein denaturation and folding, and His-tag purification. Furthermore, scFvs are less stable and difficult to store. In order to produce a molecule that not only retains the adsorption specificity of the soluble scFv expressed by phage #3 in Example 1, but also can be purified by standard procedures and is stable and easy to store, the variable region of the heavy chain of the soluble scFv expressed by phage #3 in Example 1 (VH) coding DNA and light chain variable region (VK) coding sequences were amplified by PCR and integrated into the amplifiable expression vectors pIdmkappa-VK and pIdmIgG-VH using molecular cloning techniques, which also contained...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-idiotype antibody for a human CD22 antibody, and an application thereof. The anti-idiotype antibody for the human CD22 antibody comprises three antibody heavy chain complementary determining regions and three antibody light chain complementary determining regions, wherein amino acid sequences of the three antibody heavy chain complementary determining regions are shown as 31-35 sites, 50-66 sites and 99-106 sites of a sequence 1 in a sequence table respectively; and amino acid sequences of the three antibody light chain complementary determining regions are shown as 154-168 sites, 184-190 sites and 223-231 sites of a sequence 1 in the sequence table. The anti-idiotype antibody for the human CD22 antibody can inhibit combination of the human CD22 antibody with a natural ligand of human CD22 antigen.

Description

technical field [0001] The present invention relates to anti-idiotypic antibody against human CD22 antibody and application thereof. Background technique [0002] Targeted therapy using monoclonal antibodies (MAbs) is not a novel or complicated concept. However, the implementation of this concept involves the integration of multi-disciplinary knowledge and technologies, including antibody molecular design, cell line optimization, industrial production, purification, formulation optimization and various quality control tests to ensure that the produced monoclonal antibody drugs can achieve the expected clinical effect. So far, hundreds of therapeutic monoclonal antibody products for various indications are in various stages of clinical trials. Correspondingly, a large number of concepts and technical means based on or derived from antibodies are changing with the development of the monoclonal antibody industry, in order to expand the application range of existing products. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/42C12N15/13C12N15/63C12N1/21C12N1/19C12N1/15C12N1/13C12N5/10G01N33/68G01N33/554G01N33/53
Inventor 梁瑞安
Owner SINOMAB BIOSCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com